| Characteristics | All (N = 50) | LR free survival | p-value | Overall survival | p-value | |||
| Median LRFS (months) | 3 years LRFS | Median OS (months) | 3 years OS | |||||
| All patients |
|
| NR | 83.6% |
| NR | 60.8% |
|
| Age (years) |
|
|
|
|
|
|
|
|
| ≤50 years | 17 | (38.3%) | NR | 91.3% | 0.119§ | NR | 91.3% | <0.001§ |
| >50 years | 33 | (61.7%) | NR | 75% | 24 | 41.1% | ||
| Size (cm) |
|
|
|
|
|
|
|
|
| <5 cm | 18 | 36% | NR | 91.7% | 0.087§ | NR | 91.7% | <0.001§ |
| ≥5 cm | 32 | 64% | NR | 73.7% | 24 | 39.4% | ||
| Grade |
|
|
|
|
|
|
|
|
| Grade I | 7 | (16.7%) | NR | 100% | 0.139§ | NR | 100% | <0.001§ |
| Grade II | 13 | (25%) | NR | 86.7% | NR | 86.7% | ||
| Grade III | 30 | (58.3%) | NR | 72.2% | 24 | 37.6% | ||
| Lymph node |
|
|
|
|
|
|
|
|
| Negative | 32 | (31.7%) | NR | 100% | 0.010§ | NR | 100% | <0.001§ |
| Positive | 18 | (68.3%) | NR | 70.4% | 27 | 41.6% | ||
| T |
|
|
|
|
|
|
|
|
| T1 | 10 | (21.7%) | NR | 84.6% | 0.028§ | NR | 84.6% | <0.001§ |
| T2 | 22 | (18.3%) | NR | 100% | NR | 100% | ||
| T3 | 10 | (36.7%) | NR | 77.8% | NR | 62% | ||
| T4 | 18 | (23.3%) | 20 | 0% | 17 | 0% | ||
| N |
|
|
|
|
|
|
|
|
| N0 | 6 | (31.7%) | NR | 100% | 0.006§ | NR | 100% | <0.001§ |
| N1 | 16 | (11.7%) | NR | 71.4% | NR | 71.4% | ||
| N2 | 8 | (35%) | NR | 78.6% | 28 | 45.4% | ||
| N3 | 10 | (21.7%) | 20 | 33.3% | 17 | 20.5% | ||
| Stage |
|
|
|
|
|
|
|
|
| Stage I | 8 | (15%) | NR | 100% | 0.226§ | NR | 100% | <0.001§ |
| Stage II | 10 | (23.3%) | NR | 85.7% | NR | 85.7% | ||
| Stage III | 22 | (35%) | NR | 75% | NR | 66.7% | ||
| Stage IV | 10 | (26.7%) | --- | --- | 17.5% | 0% | ||
| FOXC2 |
|
|
|
|
|
|
|
|
| Low | 23 | (38.3%) | NR | 100% | 0.001§ | NR | 100% | <0.001§ |
| High | 37 | (61.7%) | NR | 64.3% | 24 | 34.8% | ||
| YKL-40 |
|
|
|
|
|
|
|
|
| Low | 23 | (55%) | NR | 93.9% | <0.001§ | NR | 93.9% | <0.001§ |
| High | 27 | (45%) | NR | 50% | 23 | 17.1% | ||